Welcome to our dedicated page for Paysign SEC filings (Ticker: PAYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Paysign, Inc. filings document formal disclosures for a Nevada public company providing patient affordability programs, donor compensation solutions, engagement and management platforms, and integrated payment processing. Recent Form 8-K reports furnish operating results and financial-condition updates tied to quarterly and annual earnings releases.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board and committee responsibilities, executive compensation, and beneficial ownership of Paysign securities. Other current reports include Regulation FD disclosures related to stockholder derivative action settlement materials, giving the filing record governance, litigation, ownership and reporting-context coverage in addition to financial results.
Paysign, Inc. CEO and 10% owner Mark Newcomer reported selling 150,000 shares of Common Stock on August 6, 2026 at a weighted average price of $11.8757 per share, in multiple trades between $11.2444 and $12.4641. The sale was effected under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, and Newcomer continues to hold 9,163,002 shares directly after the transaction.
Paysign, Inc. director Dennis L. Triplett exercised a stock grant on August 4, 2026, converting 20,000 shares from a derivative “Stock Grant” into 20,000 shares of common stock at $0.0000 per share. The shares relate to a grant received August 4, 2025 that vested August 4, 2026. After this transaction, he directly holds 290,000 shares of Paysign common stock. These transactions were not marked as made pursuant to a Rule 10b5-1 trading plan.
Paysign, Inc. director Jeffrey B. Newman exercised a stock grant, converting 20,000 derivative shares into 20,000 shares of common stock on August 04, 2026. The underlying grant for 20,000 shares was awarded on August 04, 2025 and fully vested by the filing date. Following the transaction he directly owned 90,000 shares of Paysign common stock.
Paysign, Inc. director Bruce A. Mina reported the vesting and conversion of a prior stock grant into 20,000 shares of common stock on August 04, 2026. The award was originally granted on August 04, 2025 and has now fully vested, bringing his directly held common stock to 278,500 shares.
Paysign, Inc. director Henry Daniel R reported exercising a stock grant covering 20,000 shares of common stock on August 4, 2026. The derivative Stock Grant for 20,000 underlying shares was converted into common stock at a reported price of $0.0000 per share, bringing his direct holdings to 169,884.498 common shares.
Paysign, Inc. reported sharp growth for the three and six months ended June 30, 2026, with total revenues of $28,252,071 for the quarter and $56,290,495 year-to-date, driven mainly by plasma and pharma patient affordability programs.
Quarterly plasma revenue rose to $13,040,540 and pharma revenue to $14,649,133, supporting gross margin expansion to 63.3%. Net income increased to $6,756,537 for the quarter and $12,195,455 for six months, reflecting operating leverage, higher interest income and a $990,000 fair value gain from eliminating the Gamma contingent consideration liability.
The company ended June 30, 2026 with total assets of $316,989,606, including cash of $27,372,858 and restricted cash of $149,109,681, against customer card funding liabilities of $148,196,011. Management highlights accelerated growth in pharma claim volumes and continues to invest in technology, compliance, customer service and sales to support expansion.
Paysign, Inc. reported record second quarter 2026 revenue of $28.25 million, up 48.1% from a year earlier, driven by strong growth in both pharma and plasma. Pharma revenue rose to $14.65 million, up 88.9%, while plasma revenue increased to $13.04 million, up 21.4%.
Profitability improved sharply, with gross margin at 63.3% and operating margin at 24.8% (21.3% excluding a fair value gain on contingent consideration). GAAP net income reached $6.76 million, or $0.11 per diluted share, versus $1.39 million, or $0.02, in Q2 2025. Adjusted EBITDA was $9.61 million, up 113.0%.
The balance sheet showed $27.37 million of unrestricted cash and no bank debt, plus $149.11 million of restricted cash. Based on first-half strength, management raised full-year 2026 guidance to revenue of $114–$117 million and Adjusted EBITDA of $35–$38 million, with higher outlooks for net income and EPS.
Paysign, Inc. CEO and 10% owner Mark Newcomer reported the vesting of restricted stock covering 150,000 shares on July 31, 2026, which converted into an equal number of common shares. In a related transaction, 59,025 shares were withheld by the issuer at $8.96 per share to satisfy tax withholding obligations. The restricted stock grant vests one-fifth each year from July 31, 2022 through July 31, 2027.
Paysign, Inc. Chief Legal Officer Robert Strobo reported the vesting and conversion of 64,000 shares of restricted stock into common stock on July 31, 2026. The award vests in five equal annual installments from July 31, 2022 to July 31, 2027. To cover tax obligations from this vesting, 25,184 shares of common stock were withheld by the issuer at $8.96 per share.
Paysign, Inc. EVP, EFT Operations Joan M. Herman reported equity compensation activity on July 31, 2026. A derivative "Stock Grant" tied to 36,000 restricted shares was exercised/vested into 36,000 shares of common stock at no cost, with 13,780 shares withheld at $8.96 per share to cover tax obligations under a grant that vests one-fifth annually from a July 31, 2022 commencement date.